Capital Stock and Reserves - Additional Information (Details) $ / shares in Units, $ / shares in Units, ¥ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 31, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2022
HKD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
$ / shares
shares
|
Sep. 30, 2021
HKD ($)
$ / shares
shares
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2022
HKD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
$ / shares
|
Dec. 31, 2021
USD ($)
shares
|
Dec. 31, 2021
CNY (¥)
shares
|
Jul. 28, 2022
shares
|
Jun. 23, 2022
shares
|
Apr. 28, 2022
shares
|
Sep. 30, 2021
CNY (¥)
|
May 06, 2021
shares
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Share-based compensation costs recorded for the period | $ 5,400,000 | $ 6,100,000 | $ 19,100,000 | $ 18,200,000 | ||||||||||||
| Stock-based compensation expense | $ 5,404,000 | $ 6,109,000 | $ 19,093,000 | $ 18,211,000 | ||||||||||||
| Maximum number of shares of common stock may be issued for outstanding PSU | shares | 55,973,443 | 55,973,443 | 58,653,642 | 58,653,642 | ||||||||||||
| Common shares purchased in open market by trustee in connection with RSUs | shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||
| Number of treasury shares held in trust for future settlement of share based awards | shares | 0 | 0 | 0 | 0 | ||||||||||||
| Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares | 6,178,413 | 6,178,413 | 6,115,389 | 6,115,389 | 6,178,413 | 6,178,413 | 6,115,389 | |||||||||
| Percentage of statutory net profits to statutory surplus reserve to be appropriated | 10.00% | 10.00% | ||||||||||||||
| Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital,percent. | 50.00% | 50.00% | ||||||||||||||
| Statutory surplus reserve appropriated | $ 0 | $ 5,600,000 | $ 0 | $ 5,600,000 | $ 5,600,000 | ¥ 36.4 | ||||||||||
| Dividends declared and paid | $ 20,400,000 | ¥ 131.6 | ||||||||||||||
| Statutory surplus reserve to its subsidiaries registered capital percent | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||
| Subsequent Event [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Repurchase of common shares | shares | 1,129,774 | |||||||||||||||
| Stock Acquired, Average Cost per Share | $ / shares | $ 13.96 | |||||||||||||||
| Change in ownership interest related to IMAX China common share repurchases | $ 15,800,000 | |||||||||||||||
| IMAX China | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Details of the share repurchase program | In 2021, IMAX China's shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program expired on the date of the 2022 Annual General Meeting of IMAX China on June 23, 2022. During the 2022 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 23, 2022 (34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. | In 2021, IMAX China's shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program expired on the date of the 2022 Annual General Meeting of IMAX China on June 23, 2022. During the 2022 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 23, 2022 (34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. | ||||||||||||||
| Stock Repurchase Program Expiration Date | Jun. 23, 2022 | Jun. 23, 2022 | May 06, 2021 | |||||||||||||
| Repurchase of common shares | shares | 1,513,800 | 1,513,800 | 3,569,000 | 3,569,000 | 2,961,800 | 2,961,800 | 3,569,000 | |||||||||
| Stock Acquired, Average Cost per Share | (per share) | $ 0.79 | $ 6.20 | $ 1.40 | $ 10.90 | $ 1.02 | $ 8.00 | $ 1.40 | $ 10.90 | ||||||||
| Change in ownership interest related to IMAX China common share repurchases | $ 1,200,000 | $ 9,400,000 | $ 38.9 | $ 3,000,000.0 | $ 23,700,000 | $ 5.0 | ||||||||||
| Stock Repurchase Program, maximum percentage of shares to be repurchased | 10.00% | 10.00% | ||||||||||||||
| Stock Repurchase Program, Authorized number of shares | shares | 34,063,480 | 34,835,824 | ||||||||||||||
| Parent [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Details of the share repurchase program | April 28, 2022 and July 28, 2022, the Company's Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $200.0 million in the share repurchase program, respectively. With the increase of $200.0 million, the Company's total share repurchase authority is $400.0 million under the current share repurchase program. As of September 30, 2022, the Company has $220.1 million available under its approved repurchased program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. | April 28, 2022 and July 28, 2022, the Company's Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $200.0 million in the share repurchase program, respectively. With the increase of $200.0 million, the Company's total share repurchase authority is $400.0 million under the current share repurchase program. As of September 30, 2022, the Company has $220.1 million available under its approved repurchased program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. | ||||||||||||||
| Stock Repurchase Program, Authorized Amount | $ 220,100,000 | $ 220,100,000 | ||||||||||||||
| Stock Repurchase Program Expiration Date | Jun. 30, 2023 | Jun. 30, 2023 | ||||||||||||||
| Repurchase of common shares | shares | 418,496 | 418,496 | 316,812 | 316,812 | 3,501,696 | 3,501,696 | 316,812 | |||||||||
| Stock Acquired, Average Cost per Share | $ / shares | $ 14.62 | $ 14.53 | $ 15.82 | $ 14.53 | ||||||||||||
| Change in ownership interest related to IMAX China common share repurchases | $ 6,100,000 | $ 4,600,000 | $ 55,400,000 | $ 4,600,000 | ||||||||||||
| Stock Repurchase Program, Authorized number of shares | shares | 200,000,000.0 | 200,000,000.0 | ||||||||||||||
| Statutory surplus reserve appropriated | 3,900,000 | 3,900,000 | $ 3,900,000 | |||||||||||||
| Parent [Member] | Maximum [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock Repurchase Program, Authorized Amount | 400,000,000.0 | 400,000,000.0 | ||||||||||||||
| Non-controlling Interests [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Change in ownership interest related to IMAX China common share repurchases | 343,000 | 1,371,000 | 1,644,000 | 1,371,000 | ||||||||||||
| Statutory surplus reserve appropriated | 1,700,000 | 1,700,000 | $ 1,700,000 | |||||||||||||
| Restricted Share Units [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock-based compensation expense | $ 3,516,000 | $ 3,900,000 | $ 11,405,000 | $ 11,524,000 | ||||||||||||
| Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares | 1,329,014 | 1,329,014 | 1,592,965 | 1,592,965 | 1,329,014 | 1,329,014 | 1,592,965 | |||||||||
| Restricted Share Units [Member] | Non-Employee Directors [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock-based compensation expense | $ 0 | $ 1,300,000 | ||||||||||||||
| Restricted Share Units [Member] | Non-Employee Directors [Member] | IMAX China | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock-based compensation expense | $ 0 | $ 0 | ||||||||||||||
| Employee Stock Option [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock-based compensation expense | $ 120,000 | $ 253,000 | $ 449,000 | $ 808,000 | ||||||||||||
| Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares | 3,604,739 | 3,604,739 | 3,738,504 | 3,738,504 | 3,604,739 | 3,604,739 | 3,738,504 | |||||||||
| Performance Stock Units [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Stock-based compensation expense | $ 1,864,000 | $ 1,183,000 | $ 5,317,000 | $ 3,169,000 | ||||||||||||
| Stock based awards vesting period | 3 years | 3 years | ||||||||||||||
| Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares | 1,244,660 | 1,244,660 | 783,920 | 783,920 | 1,244,660 | 1,244,660 | 783,920 | |||||||||
| Performance Stock Units [Member] | Minimum [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | 0.00% | 0.00% | ||||||||||||||
| Performance Stock Units [Member] | Maximum [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | 175.00% | 175.00% | ||||||||||||||
| Performance Stock Units [Member] | EBITDA | Maximum [Member] | ||||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||
| Maximum number of shares of common stock may be issued for outstanding PSU | shares | 1,636,735 | 1,636,735 | ||||||||||||||